|Description||Non-specific inhibitor of cAMP and cGMP phosphodiesterases. The increase in cAMP level as a result of phosphodiesterase inhibition by IBMX activates PKA leading to decreased proliferation, increased differentiation, and induction of apoptosis. IBMX inhibits phenylephrine-induced release of 5-hydroxytryptamine from neuroendocrine epithelial cells of the airway mucosa (IC50: 1.3 μM). Also serves as an adenosine receptor antagonist. Shown to inhibit ion channels in the neuromuscular junction, GH3 cells, and vascular smooth muscle cells. Induces calcium release from intracellular stores in sensory neurons.|
|Synonyms||3,9-Dihydro-1-methyl-3-(2-methylpropyl)-1H-purine-2,6-dione; IBMX; 1-Methyl-3-isobutylxanthine; IMX; Isobutylmethylxanthine; Methylisobutylxanthine; NSC 165960; SC 2964|
CVT5440 is a selective, high affinity A(2B) adenosine receptor antagonist. It may has the potential treatment of asthma and has good selectivity.
KF21213 is a highly selective ligand for mapping CNS adenosine A2A receptors. The Ki values of KF21213 were 3.0 nM for the adenosine A2A receptors and >10,000 n...
An orally administered, potent and selective inhibitor of the adenosine 2a (A2a) receptor
Ticlopidine HCl is an P2 receptor inhibitor against ADP-induced platelet aggregation with IC50 of ~2 μM.
KW-3902 is a selective adenosine A1 receptor antagonist under the development of Kyowa Hakko and Merck & Co. It displays 890-fold selectivity for rat A1 recepto...
CGS 21680, an A2 adenosine receptor selective agonist, has been found to be probably effective in inducing vasorelaxation and increasing in heart rate.
AB-MECA, a adenosine derivative, is a high affinity human A3 receptor in HEK 293 cells agonist.
CGS 21680 Hydrochloride
CGS 21680 Hcl is an adenosine A2 receptor agonist with IC50 of 22 nM, exhibits 140-fold over A1 receptor.
N6-Cyclohexyladenosine is a derivative of Adenosine, a selective A1 receptor agonist with EC50 = 8.2 nM.
N-0861 racemate is the racemate of N-0861 which appears to be an effective and selective A1 adenosine receptor antagonist in humans.
Trabodenoson is a selective adenosine A1 receptor agonist. Trabodenoson can significantly reduce IOP in glaucoma and OHT patients. Phase III clinical trials for...
UP202-56, an adenosine analogue, selectively acts via A1 receptors to significantly decrease noxiously-evoked spinal c-Fos protein expression.
Rolofylline metabolite M1-cis
Rolofylline metabolite M1-cis, an active metabolite of Rolofylline, is a potent and selective adenosine A1 receptor antagonist.
CF101 is a specific agonist to the A3 adenosine receptor, which inhibits the development of colon carcinoma growth in cell cultures and xenograft murine models...
Naxifylline, a xanthine derivative, has been found to be an adenosine A1 receptor antagonist as well as diuretic agent that was once studied in heart failure an...
Sonedenoson is an adenosine A2 receptor agonist under the development of King Pharmaceuticals Research and Development. It can effectively promote rapid wound h...
GP531 is a novel riboside with similar structural and anti-ischemic properties to the adenosine-regulating agent (ARA) acadesine.
PD-117519 is a N6-substituted adenosine receptor agonist. It shows oral antihypertensive activity in pharmacological animal models. It is used as a potential an...
Rolofylline metabolite M1-trans
Rolofylline metabolite M1-trans, an active metabolite of Rolofylline, is a potent and selective adenosine A1 receptor antagonist.
LUF6000 is an allosteric modulator of the human A3 adenosine receptor (AR). It was found to be an allosteric enhancer of Emax. It exerted an Emax-enhancing effe...